

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East),
Mumbai - 400 063, India

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited Review Report on unaudited standalone financial results of Alkem Laboratories Limited for the quarter ended 30 June 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Alkem Laboratories Limited ("the Company") for the quarter ended 30 June 2022 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.



B S R & Co. LLP

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Balajirao Pothana

Partner

Mumbai

05 August 2022

Membership No.: 122632

UDIN:22122632AOHXPE4698

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Unaudited Standalone Financial Results for the Quarter ended 30 June 2022


(₹ in Million except per share data)

	Particulars	Quarter ended			Year ended
		30.06.2022 Unaudited	31.03.2022 Audited (Refer note 1)	30.06.2021 Unaudited	31.03.2022 Audited
1	Income				
	(a) Revenue from Operations	20,583.5	20,063.1	22,786.7	88,298.1
	(b) Other Income	553.1	542.3	392.1	1,998.9
	Total Income	21,136.6	20,605.4	23,178.8	90,297.0
2	Expenses				
	(a) Cost of materials consumed	6,073.1	7,660.0	6,538.1	28,497.5
	(b) Purchases of stock-in-trade	1,839.1	2,458.9	2,629.7	10,770.4
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,267.7	(1,148.7)	(41.6)	(3,609.0)
	(d) Employee benefits expense	3,870.3	3,306.8	4,022.3	14,344.9
	(e) Finance costs	220.2	130.8	90.6	379.0
	(f) Depreciation and amortisation expense	568.1	550.1	517.2	2,189.8
	(g) Other expenses	5,700.2	5,789.2	4,132.5	20,190.7
	Total Expenses	19,538.7	18,747.1	17,888.8	72,763.3
3	Profit before exceptional items and tax (1) - (2)	1,597.9	1,858.3	5,290.0	17,533.7
4	Exceptional items	-	-	-	-
5	Profit before tax (3) + (4)	1,597.9	1,858.3	5,290.0	17,533.7
6	Tax expense / (credit)				
	(a) Current tax	275.1	324.1	916.2	3,038.2
	(b) Deferred tax	(78.2)	765.4	(318.9)	(917.0)
	Total Tax Expense (a + b)	196.9	1,089.5	597.3	2,121.2
7	Profit for the period after tax (5 - 6)	1,401.0	768.8	4,692.7	15,412.5
8	Other Comprehensive Income (net of tax)				
	(a) (i) Items that will not be reclassified to profit or loss	(6.3)	(26.8)	(16.0)	(74.7)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	2.2	9.4	5.6	26.1
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income (net of tax)	(4.1)	(17.4)	(10.4)	(48.6)
9	Total Comprehensive Income for the period (7) + (8)	1,396.9	751.4	4,682.3	15,363.9
10	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1
11	Other Equity				87,197.5
12	Earnings Per Share (not annualised for the quarters)				
	(a) Basic (₹)	11.72	6.43	39.25	128.90
	(b) Diluted (₹)	11.72	6.43	39.25	128.90

Notes to the Standalone Financial results:

- 1 The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 4 August 2022 and subsequently approved by the Board of Directors at its meeting held on 5 August 2022. The auditors have issued an unmodified report on the financial results for the quarter ended 30 June 2022. The figures for the quarter ended 31 March 2022 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended 31 December 2021, which were subjected to limited review.
- 2 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.

By Order of the Board
For Alkem Laboratories Limited



B.N. Singh
Executive Chairman
DIN: 00760310

Place: Mumbai
Date: 5 August 2022